Duloxetine (Cymbalta)

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Overview

Duloxetine, marketed as Cymbalta, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain. Available in delayed-release capsules, it offers a balanced efficacy for mood and pain disorders with a favorable side effect profile compared to tricyclic antidepressants. Monitoring is required for hepatotoxicity, serotonin syndrome, and discontinuation syndrome.

Mechanism of Action

Duloxetine inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE), increasing their synaptic availability in the central nervous system. This enhances mood regulation and pain modulation via descending inhibitory pathways. It has minimal affinity for muscarinic, histaminergic, dopaminergic, or adrenergic receptors, reducing sedation and anticholinergic effects. Its balanced 5-HT/NE inhibition contributes to efficacy in both psychiatric and pain conditions.

Indications

  • Major Depressive Disorder (MDD): Adults.
  • Generalized Anxiety Disorder (GAD): Adults and children ≥7 years.
  • Diabetic Peripheral Neuropathic Pain (DPNP): Adults.
  • Fibromyalgia: Adults.
  • Chronic Musculoskeletal Pain: Adults, including chronic low back pain and osteoarthritis pain.
  • Stress Urinary Incontinence (SUI): Used in some countries for women.
  • Chemotherapy-Induced Peripheral Neuropathy: Adjunct for pain management.
  • Obsessive-Compulsive Disorder (OCD): Limited use in treatment-resistant cases.

Dosing and Administration

Indication Starting Dose Maintenance Dose Maximum Dose
Major Depressive Disorder (Adults) 20-30 mg/day 60 mg/day 120 mg/day
Generalized Anxiety Disorder (Adults) 30 mg/day 60 mg/day 120 mg/day
Generalized Anxiety Disorder (Children 7-17 years) 30 mg/day 30-60 mg/day 120 mg/day
Diabetic Peripheral Neuropathic Pain (Adults) 30 mg/day 60 mg/day 60 mg/day
Fibromyalgia (Adults) 30 mg/day for 1 week 60 mg/day 60 mg/day
Chronic Musculoskeletal Pain (Adults) 30 mg/day for 1 week 60 mg/day 60 mg/day
Stress Urinary Incontinence (Off-label, Adults) 20 mg twice daily 40 mg twice daily 80 mg/day
  • Elderly: Start at 30 mg/day for GAD; titrate cautiously to 60 mg/day; no specific adjustment for MDD or pain indications.
  • Hepatic Impairment: Avoid in severe impairment; reduce dose by 50% in mild-moderate impairment.
  • Renal Impairment: Avoid in severe impairment (CrCl <30 mL/min); no adjustment for mild-moderate.
  • Pregnancy: Category C; limited data; use only if benefits outweigh risks; risk of neonatal withdrawal.
  • Breastfeeding: Excreted in breast milk; monitor infant for sedation or poor feeding.
Clinical Pearl: Administer with food to reduce nausea; once-daily dosing is effective due to its 12-14 hour half-life, but twice-daily may be used for higher doses (e.g., 120 mg/day for MDD).

Pharmacokinetics

Parameter Details
Absorption Well absorbed; Tmax ~6 hours; bioavailability ~50% due to first-pass metabolism.
Distribution Volume of distribution ~1640 L; highly protein-bound (~95%).
Metabolism Hepatic via CYP1A2 and CYP2D6; multiple inactive metabolites.
Half-Life 12-14 hours.
Excretion Urine (~70% as metabolites, <1% unchanged); feces (~20%).
Clinical Pearl: Duloxetine’s hepatic metabolism requires caution with CYP1A2 (e.g., smoking) or CYP2D6 inhibitors; its half-life supports once-daily dosing but necessitates tapering to avoid withdrawal.

Side Effects

  • Gastrointestinal: Nausea (23%), dry mouth (14%), constipation (9%).
  • Central Nervous System: Fatigue (10%), somnolence (9%), headache (14%).
  • Other: Decreased appetite (8%), sweating (6%).

Data from clinical trials (Eli Lilly, 2023).

  • Hepatotoxicity: Rare; elevated LFTs or liver injury; monitor in hepatic risk patients.
  • Serotonin Syndrome: Risk with serotonergic drugs; symptoms include agitation, tremors, hyperthermia.
  • Suicidal Thoughts/Behavior: Increased risk in patients <25 years; monitor closely during initial treatment.
  • Hyponatremia: Rare; due to SIADH; monitor sodium in elderly or diuretic users.
  • Bleeding Risk: Increased with NSAIDs or anticoagulants due to serotonin effects on platelets.
Clinical Pearl: Nausea is most common during the first 2 weeks and often subsides; starting at 30 mg/day for 1 week can improve tolerability. Monitor for serotonin syndrome with polypharmacy.

Interactions

  • MAO Inhibitors (e.g., phenelzine): Contraindicated; risk of serotonin syndrome; allow 14-day washout.
  • CYP1A2 Inhibitors (e.g., fluvoxamine): Increase duloxetine levels; reduce dose or avoid.
  • CYP2D6 Inhibitors (e.g., paroxetine): Increase duloxetine levels; monitor for toxicity.
  • Serotonergic Drugs (e.g., SSRIs, tramadol): Increased risk of serotonin syndrome; use cautiously.
  • NSAIDs/Anticoagulants (e.g., aspirin, warfarin): Increased bleeding risk; monitor for bruising or bleeding.
Clinical Pearl: Smoking (CYP1A2 inducer) may reduce duloxetine levels by up to 30%; dose adjustments may be needed. See bleeding risk guidance.

Contraindications and Warnings

  • Hypersensitivity to duloxetine or its components.
  • Concomitant use with MAO inhibitors or within 14 days of stopping an MAOI.
  • Uncontrolled narrow-angle glaucoma.
  • Severe hepatic impairment or severe renal impairment (CrCl <30 mL/min).
  • Suicidality: Black box warning; increased risk in children, adolescents, and young adults; monitor for worsening mood.
  • Hepatotoxicity: Risk of liver injury; avoid in patients with heavy alcohol use or liver disease.
  • Orthostatic Hypotension: Risk in elderly or volume-depleted patients; monitor BP.
  • Discontinuation Syndrome: Symptoms include dizziness, nausea, irritability; taper over 1-2 weeks.
  • Bleeding Risk: Caution with NSAIDs or anticoagulants; monitor for GI bleeding.

Evidence and Guidelines

  • MDD: 60 mg/day reduced HAM-D scores by 10-12 points vs. placebo (6-8 points) in 8-week trials (J Clin Psychiatry, 2002).
  • GAD: 60-120 mg/day reduced HAM-A scores by 12-14 points vs. placebo (8-10 points) (J Clin Psychopharmacol, 2007).
  • DPNP: 60 mg/day reduced pain scores by 50% in 12-week trials (Pain, 2005).
  • Fibromyalgia: 60 mg/day improved pain and function in 12-week trials (J Rheumatol, 2008).
  • SUI: 80 mg/day reduced incontinence episodes by 50-60% vs. placebo (Am J Obstet Gynecol, 2003).
  • APA (2010): Recommended for MDD and GAD; first-line for fibromyalgia with depression.
  • NICE (2020): Suggested for GAD and neuropathic pain; monitor for hepatotoxicity.
  • EAU (2018): Supports duloxetine for stress urinary incontinence in women.

Monitoring Parameters

  • Hepatic: Baseline and periodic LFTs, especially in patients with alcohol use or liver disease.
  • Psychiatric: Monitor for suicidal thoughts, especially in first 4 weeks or dose changes.
  • Cardiovascular: Monitor BP at baseline and during dose increases; risk of hypertension.
  • Electrolytes: Monitor sodium in elderly or diuretic users for hyponatremia risk.
  • Renal: Assess CrCl in renal impairment; avoid if CrCl <30 mL/min.

Patient Education

  • What to Expect: Mood or pain improvement may take 2-4 weeks; nausea may occur initially but often resolves.
  • Managing Side Effects: Take with food to reduce nausea; report severe headache, confusion, or tremors immediately.
  • When to Seek Help: Contact your doctor for worsening mood, yellowing skin, or unusual bleeding.
  • Avoid Abrupt Stopping: Taper with your doctor to avoid withdrawal symptoms like dizziness or irritability.